logo

HITAP เข้าสู่ระบบ

ลืมรหัสผ่าน?

Systematic review and meta-analysis of intravitreal bevacizumab (Avastin®) in macular diseases

Home > Research Projects > Strategy 3 : HTA Research > Systematic review and meta-analysis of intravitreal bevacizumab (Avastin®) in macular diseases

Project Code

211-372-2555(1)

Research team

Researchers

Pattara Leelahavarong, PhD.

Thunyarata Anothaisintawee

Co - Researcher

-

Project Details

Strategies
Category
Support
Tags
Project duration

Start: 10 February 2012
End: 2 October 2012

Contact
[email protected]

Project Status

Completed - 100%

Viewer: 1807

Publish date29 August 2012 16:49

Project Summary

There is increasing impetus to use pharmaceutical interventions, ie, ranibizumab or bevacizumab, for the treatment of particular macular diseases. This study conducts the evidence synthesis to inform policy decision-making of the National List of Essential Medicines Committee that recently announced the inclusion of bevacizumab for the treatment of macular diseases in its pharmaceutical benefit package. The findings of a systematic review and meta-analysis in this study indicate that the intravitreal administration of bevacizumab is superior to nonpharmaceutical treatments for age-related macular degeneration (AMD) and diabetic macular edema (DME), but inconclusive for retinal vein occlusion, given the limited evidence. The study also failed to distinguish among the differences in terms of visual acuity improvement, reduction of central macular thickness, and response to treatment between AMD and DME patients treated with bevacizumab and those treated with ranibizumab. Although bevacizumab was not licensed for AMD and DME, the committee decided to include bevacizumab in the National List of Essential Medicines. It is expected that many patients who are in need of treatment but who are unable to afford the expensive alternative drug, ranibizumab, will be able to receive this effective treatment instead and be prevented from suffering irreversible loss of vision.

Documents

Activity

Health Intervention and Technology Assessment Program Foundation
Head Office : 88/22 Moo 4, 6th Building, 6th Floor, Department of Health, Ministry of Public Health, Tiwanon Road, Taladkwan Subdistrict, Muang Nonthaburi District, Nonthaburi 11000, Thailand


Tel. : +662-590-4549, +662-590-4374-5
Fax : +662-590-4369
E-mail : [email protected]
Website : www.hitap.net


© Copyright - HITAP 2014
Top